Comparison of Upgrading to Conduction System Pacing and Biventricular Pacing in Patients with Pacemaker-induced Cardiomyopathy

Author:

Chen Ying1ORCID,Ma Peipei1,Yang Yiheng1,Li Guocao1,Ma Chengming2,Fa Qing1,Gao Lianjun1,Xia Yunlong2,Dong Yingxue2ORCID

Affiliation:

1. First Affiliated Hospital of Dalian Medical University

2. First Affliated Hospital of Dalian Medical University: First Affiliated Hospital of Dalian Medical University

Abstract

Abstract Background: Pacemaker-induced cardiomyopathy (PICM) is common in patients with right ventricular pacing (RVP). We are still not clear whether the conduction system pacing (CSP) upgrade is better than the traditional biventricular pacing (BiVP) upgrade. Objective: To illustrate the performances of different upgrade modalities in patients with PICM. Methods: All patients with PICM were consecutively enrolled and followed for at least one year regardless of resynchronization upgrade from 2017 to 2021. Clinical data, including echocardiographic parameters, electrocardiogram measurements and cardiac function, were collected and compared. Results: A total of 73 patients were enrolled. Forty-eight patients had a resynchronization upgrade including 11 patients with BiVP, 24 patients with HBP and 13 patients with LBBP. The QRS duration (127.81±31.89 vs. 177.08±34.35ms, P<0.001), NYHA class (2.28±0.70 vs. 3.04±0.54, P<0.05), left ventricular end-diastolic diameter (LVEDD) (54.08±4.80 vs. 57.50±4.85mm, P<0.05) and LVEF (44.46±6.39 vs. 33.15±5.25%, P<0.001) improved significantly in patients with upgrade, while no improvement was detected in patients without upgrade. The range of improvement in QRS duration (59.65±11.71 vs. 34.67±13.32ms, P<0.001), LVEDD (5.80±1.71 vs. 3.16±1.35mm, P<0.001), LVEF (12.80±3.66 vs. 6.93±3.04%, P<0.001) were more significant in patients with CSP compared with BiVP. However, the range of improvement of LVEDD and LVEF were not different between LBBP and HBP. The threshold in LBBP was lower than HBP (1.01±0.43 vs. 1.33±0.32V, P=0.019). Conclusion: The improvement of clinical outcomes in CSP were more significant than in BiVP. CSP may be an alternative therapy of CRT in patients with PICM. LBBP would be a better choice for achieving lower thresholds compared with HBP.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3